Applied Evidence

Thrombocytopenia and neutropenia: A structured approach to evaluation

J Fam Pract. 2018 July;67(7):E1-E8

From The Journal of Family Practice | 2018;67(7):E1-E8.

References

1. Wong EY, Rose MG. Why does my patient have thrombocytopenia? Hematol Oncol Clin North Am. 2012;26:231-252.

2. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007;357:580-587.

3. University of Oklahoma Health Sciences Center. Database for Drug–induced thrombocytopenia from group patient reports: an update. Available at: http://www.ouhsc.edu/platelets/InternetPostingGroupFrames2014.htm. Accessed May 7, 2018.

4. Sniecinski RM, Hursting MJ, Paidas MJ, et al. Etiology and assessment of hypercoagulability with lessons from heparin-induced thrombocytopenia. Anesth Analg. 2011;112:46-58.

5. Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. Crit Care Clin. 2011;27:805-823.

6. Connell NT, Sweeney JD. Does my patient have life- or limb-threatening thrombocytopenia? Hematol Oncol Clin North Am. 2012;26:369-382.

7. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371:654-666.

8. Hanly JG. Antiphospholipid syndrome: an overview. CMAJ. 2003;168:1675-1682.

9. Sekhon SS, Roy V. Thrombocytopenia in adults: a practical approach to evaluation and management. South Med J. 2006;99:491-498.

10. Gauer RL, Braun MM. Thrombocytopenia. Am Fam Physician. 2012;85:612-622.

11. Bratton RL, Corey R. Tick-borne disease. Am Fam Physician. 2005;71:2323-2330.

12. Yeh JJ, Tsai S, Wu DC, et al. P-selectin-dependent platelet aggregation and apoptosis may explain the decrease in platelet count during Helicobacter pylori infection. Blood. 2010;115:4247-4253.

13. Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systemic review. Blood. 2009;113:1231-1240.

14. Weinzierl EP, Arber DA. The differential diagnosis and bone marrow evaluation of new-onset pancytopenia. Am J Clin Pathol. 2013;139:9-29.

15. Peck-Radosavljevic M. Hypersplenism. Eur J Gastroenterol Hepatol. 2001;13:317-323.

16. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117:4190-4207.

17. Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Int Med. 2015;162:205-213.

18. Palmblad J, Dufour C, Papadaki HA. How we diagnose neutropenia in the adult and elderly patient. Haematologica. 2014;99:1130-1133.

19. Hsieh MM, Everhart JE, Byrd-Holt DD, et al. Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences. Ann Intern Med. 2007;146:486-492.

20. Gibson C, Berliner N. How we evaluate and treat neutropenia in adults. Blood. 2014;124:1251-1258.

21. Urabe A. Clinical features of the neutropenic host: definitions and initial evaluation. CID. 2004;39(suppl 1):S53-S55.

22. Dale DC, Hammond WP 4th. Cyclic neutropenia: a clinical review. Blood Rev. 1988;2:178-185.

23. Munshi HG, Montgomery RB. Severe neutropenia: a diagnostic approach. West J Med. 2000;172:248-252.

24. Pisciotta AV. Drug-induced agranulocytosis peripheral destruction of polymorphonuclear leukocytes and their marrow precursors. Blood Rev. 1990;4:226-237.

25. Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med. 2007;146:657-665.

26. Bhatt V, Saleem A. Review: drug-induced neutropenia – pathophysiology, clinical features, and management. Ann Clin Lab Sci. 2004;34:131-137.

27. Newburger PE, Dale DC. Evaluation and management of patients with isolated neutropenia. Semin Hematol. 2013;50:198-206.

28. Bakken JS, Krueth J, Wilson-Nordskog C, et al. Clinical and laboratory characteristics of human granulcytic ehrlichiosis. JAMA. 1996;275:199-205.

29. Hall GW, Schwartz RP. White blood cell count and differential in Rocky Mountain spotted fever. NC Med J. 1979;40:212-214.

30. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146:797-808.

31. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64:2677-2686.

Is the patient severely ill? 

The prognosis of the patient is related both to the etiology of the neutropenia, as well as to the nadir of the neutrophil count. Patients who have an ANC <500 cells/mcL or who have inadequate bone marrow reserves are at highest risk for an overwhelming infection.^20,21 The absence of oral ulcers and gingivitis and/or the presence of purulent material at the site of an infection are signs of adequate bone marrow reserves.

Additionally, neutropenia may be the source—or the result—of a serious life-threatening illness. This distinction may not be readily apparent at the time of the patient’s presentation. If signs or symptoms of a severe illness are apparent (fever, hypotension, tachycardia, ANC <500 cells/mcL), admit the patient to the hospital for evaluation and initiation of antibiotics.

Is the neutropenia chronic?

A review of previous CBCs will identify whether this condition is new or chronic. A persistent, mild neutropenia (ANC 1000-1500 cells/mcL) in a healthy individual is consistent with benign familial or ethnic neutropenia (see TABLE 6).²⁰ If prior CBCs are unavailable, then a diagnosis of chronic neutropenia may be established by verifying the persistence of mild neutropenia over time.

Cyclic neutropenia is a periodic neutropenia (occurring every 2-5 weeks) associated with mild illnesses that are related to the nadir of the neutrophil count. The diagnosis is established by obtaining serial CBCs twice weekly for 4 to 6 weeks, which reflect cycling of the neutrophil count.^20,22

Are any medications contributing to the neutropenia?

Medications that suppress bone marrow or that interfere with other immune-mediated processes are the most common cause of acquired neutropenia.²³ Drug-induced agranulocytosis is defined as an ANC <500 cells/mcL due to exposure to a drug that results in immunologic or cytotoxic destruction of neutrophils.²⁴

A persistent, mild neutropenia in a healthy individual is consistent with benign familial or ethnic neutropenia.

A systematic review of case reports of drug-induced agranulocytosis (a decrease in peripheral neutrophil count to <500 cells/mcL) revealed that although at least 125 drugs were probably related to agranulocytosis, only 11 drugs were responsible for 50% of cases (carbimazole, clozapine, dapsone, dipyrone, methimazole, penicillin G, procainamide, propylthiouracil, rituximab, sulfasalazine, and ticlopidine), and fatality rates were higher (10% vs 3%) among those patients with a nadir <100 cells/mcL.²⁵ TABLE 7²⁵ lists medications that can be associated with agranulocytosis. Depending on prior exposure to a drug, neutropenia/agranulocytosis can occur within hours to months of exposure to the causal drug and can take a few days to 3 weeks to resolve after cessation.^25,26

Continue to: Has the patient had any recent illnesses?